Abstract
Lanadelumab is a fully human monoclonal antibody (IgG1κ) against plasma kallikrein. Itʼs a novel, effective and well tolerated therapeutic option for prevention of hereditary angioedema attacks.
Lanadelumab is administered subcutaneously and has been approved for use in patiens 12 years of age and older.
